Page last updated: 2024-12-11
coronardine
Description
coronardine: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6426909 |
| CHEBI ID | 3887 |
| SCHEMBL ID | 2343450 |
| MeSH ID | M0058258 |
Synonyms (12)
| Synonym |
|---|
| coronardine |
| chebi:3887 , |
| einecs 207-398-7 |
| nsc 127490 |
| methyl ibogamine-18-carboxylate |
| SCHEMBL2343450 |
| NVVDQMVGALBDGE-PZXGUROGSA-N |
| DTXSID60963642 |
| HY-121118 |
| methyl (1s,15r,17s,18s)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate |
| CS-0079497 |
| FS-8035 |
Roles (4)
| Role | Description |
|---|
| antileishmanial agent | An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| monoterpenoid indole alkaloid | A terpenoid indole alkaloid which is biosynthesised from L-tryptophan and diisoprenoid (usually secolaganin) building blocks. |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| organic heteropentacyclic compound | |
| alkaloid ester | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.21
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.21 (24.57) | | Research Supply Index | 2.94 (2.92) | | Research Growth Index | 5.15 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |